INTRODUCTION {#S1}
============

Human herpesvirus 6B (HHV-6B) reactivates in 60--90% of cord blood transplant (CBT) recipients and is associated with significant morbidity, particularly due to limbic encephalitis, which occurs in up to 10% of CBT recipients^[@R1]--[@R4]^. With a prospective study of 315 hematopoietic cell transplantation (HCT) recipients, we previously demonstrated that HHV-6 viremia is also associated with less fulminant central nervous system (CNS) dysfunction as measured by delirium and neurocognitive decline^[@R5]^. This prospective study examines whether HHV-6 reactivation is associated with an increased risk for delirium specifically after CBT. Additionally, our center changed antiviral prophylaxis strategies for cytomegalovirus (CMV) seropositive CBT recipients during enrollment, and we analyze the effect of intensified prophylaxis on HHV-6 reactivation.

SUBJECTS AND METHODS {#S2}
====================

Patients {#S3}
--------

Thirty-one patients undergoing CBT from April 2005 through August 2008 were enrolled as part of a larger study^[@R5]^. An additional cohort of 30 CBT recipients was enrolled between July 2009 and August 2011 following the same protocol. Patients with evidence of inherited chromosomally integrated (ci)HHV-6, defined as increasing HHV-6 plasma DNA levels in the first two weeks after HCT and persistent levels ≥100 copies per/mL in ≥80% of subsequent plasma samples, were excluded^[@R6]^. Of the 61 patients enrolled, 14 withdrew before contributing data, one was excluded due to suspected inherited ciHHV-6, and two were excluded for peri-HCT use of foscarnet, leaving a final cohort of 44 patients. Demographic and clinical data, including use of medications known to cause delirium and antivirals active against HHV-6, were collected from clinical records and databases and defined as previously described^[@R5]^.

Antiviral Prophylaxis {#S4}
---------------------

Antiviral prophylaxis strategies for CMV seropositive patients changed in June 2008 from valacyclovir 500 mg twice daily for herpes simplex and varicella zoster viruses to an intensified strategy using ganciclovir 5 mg/kg daily on days -8 to -2 during conditioning followed by valacyclovir 2 g every 8 hours for the first 100 days after CBT^[@R7]^.

HHV-6 Testing {#S5}
-------------

Patients had twice-weekly plasma specimens tested for HHV-6 through day 84 after CBT. Care teams and investigators were blinded to results, which were obtained after finalization of endpoints. Routine testing for HHV-6 was not performed at our center except in the setting of neurologic symptoms. HHV-6 was quantified using PCR as previously described^[@R5]^. The lower limit of detection was 1 copy of HHV-6 DNA/reaction (25 copies/mL of plasma). A conserved region of the U94 gene was amplified to distinguish between species HHV-6A and HHV-6B.

Delirium Testing {#S6}
----------------

Neuropsychiatric assessments for delirium were obtained thrice-weekly through day 56 and once weekly days 57 to 84 after CBT. Delirium was assessed using the Delirium Rating Scale (DRS) ^[@R8]^, a 10-item scale assessing delirium symptoms over 24 hours using information from patient interview, family reports, and clinical and laboratory data. Patients too ill to undergo DRS assessment were assessed using *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* (DSM-IV) criteria for delirium^[@R9]^. A delirium episode was defined as a DRS score more than 12 or delirium based on the DSM-IV checklist on at least 2 of 3 consecutive assessments^[@R10]^. Overall, 35 (80%) of 44 patients were assessed for delirium; those lacking assessments were either \<3 years old or unable to communicate. The protocol did not include neuroimaging or cerebrospinal fluid (CSF) testing; results from these studies were collected when they were obtained clinically.

Statistical Analyses {#S7}
--------------------

The primary endpoint was delirium measured as a longitudinal binary outcome, modeled using logistic regression with generalized estimating equations to evaluate odds ratios (OR) and associated 95% confidence intervals (CI) with robust variance estimates to account for within subject correlations^[@R11]^. The primary risk factor of interest, any level of HHV-6 detection, was modeled as a time-dependent dichotomous variable. To evaluate a quantitative association between HHV-6 DNA detection and the endpoint, we also used the median maximum per patient (785 copies/mL) and maximum upper quartile (6,154 copies/mL) as thresholds for comparison. At each time point that delirium was assessed, HHV-6 was coded as positive if at the current or a prior time point the subject had detection at any level, \>median maximum, or in the maximum upper quartile.

Multivariable Cox models were used to evaluate hazard ratios (HR) and associated CIs for the risk of HHV-6 reactivation. The effect of intensified antiviral prophylaxis on HHV-6 reactivation and delirium was assessed, and cumulative incidence curves for HHV-6 reactivation were generated, censoring at day of last contact and treating death as a competing risk event. Due to the relatively small sample size, analyses were restricted to bivariable models. Variables with a *P*-value \<0.2 in univariable analysis were candidates for bivariable analyses. Statistical significance was defined as 2-sided *P* \<0.05. SAS version 9.3 (SAS Institute, Cary, NC) was used for analyses.

RESULTS {#S8}
=======

Patient and virologic characteristics are presented in [Table 1](#T1){ref-type="table"}. HHV-6 was detected in 29 (66%) of the 44 patients by day 84 after CBT. The median maximum viral load in the whole cohort was 785 copies/mL (interquartile range \[IQR\], 0 - 6,154) detected at a median of 24 days after CBT (IQR, 19--27 days). Among patients who reactivated HHV-6, the median maximum viral load was 2,945 (IQR, 960--19,252). Species typing demonstrated HHV-6B in all tested patients (two were not tested).

Among 35 subjects assessed for delirium, 11 (31%) had any delirium (at least 1 positive assessment), and 9 (26%) had \>1 positive delirium assessment on consecutive testing (i.e. a delirium episode) lasting a median of 3 days (IQR, 3--6). In univariable logistic regression models, a delirium episode was more likely in patients with HHV-6 levels \>median (OR, 2.88; 95% CI, 0.97--8.59; p*=*0.06) and a comorbidity score ≥3 (OR, 7.93; 95% CI, 1.53--40.99; p*=*0.01). Using a threshold of HHV-6 detection in the upper quartile resulted in a higher odds for delirium (OR=4.54) but wider CI due to limited events. The association between HHV-6 \>median and delirium was maintained in a series of bivariable models ([Figure 1](#F1){ref-type="fig"}).

Cerebrospinal fluid (CSF) was obtained by care providers in 6 patients. Five of these patients had delirium assessments and 2 had a delirium episode within 1 week of CSF sampling. One of these patients did not have HHV-6 in CSF or plasma, whereas the other had HHV-6 detected in CSF samples and plasma samples within 1 week. This was the only patient with findings consistent with HHV-6 encephalitis, the incidence of which was 2.3% (1/44 patients). HHV-6 was detected in the CSF of 2 additional patients with headache but without delirium.

There were no patient characteristics associated with any level HHV-6 reactivation. Risk of HHV-6 \>median was increased by double CBT (vs. single; hazard ratio \[HR\], 3.45; 95% CI, 1.01--11.76; p=0.05) and acute graft-versus-host disease grades 3--4 (HR, 2.41; 95% CI, 0.94--6.19; p=0.07) but reduced in patients receiving intensified antiviral prophylaxis (HR, 0.46; 95% CI, 0.18--1.17; p=0.10; [Figure 2](#F2){ref-type="fig"}). A multivariable model adjusted for these variables demonstrated that intensified antiviral prophylaxis maintained its effect on mitigating HHV-6 reactivation \>median (aHR, 0.39; 95% CI, 0.14--1.08; p=0.07; [Table 2](#T2){ref-type="table"}). Intensified prophylaxis had an even more apparent effect on reducing HHV-6 detection in the upper quartile (HR, 0.13; 95% CI 0.02--1.03; p=0.05). We could not meaningfully analyze the effect of intensified antiviral prophylaxis on delirium or death given the number of subjects and events.

Discussion {#S9}
==========

We demonstrate a quantitative association between HHV-6 reactivation and delirium in a prospective cohort of CBT recipients. We also report that intensified antiviral prophylaxis with high-dose valacylovir may mitigate HHV-6 reactivation. The results are of particular importance to CBT recipients who reactivate HHV-6 more frequently and at higher levels with an attendant increase in morbidity, likely due to the immunologically immature allograft^[@R1]--[@R3],[@R12]^. This study helps to establish an objective clinical endpoint and further impetus for investigating the benefit of HHV-6 screening, prophylaxis, and treatment after CBT.

The association of HHV-6 reactivation with delirium expands our appreciation for the potential impact of this virus beyond the 2--10% of CBT recipients affected by overt HHV-6 encephalitis^[@R1],[@R2],[@R4],[@R13]^. Nevertheless, our understanding of the significance of HHV-6 DNA detection in the blood or CSF, how well this correlates with end-organ disease, and the mechanisms underlying associated morbidity remains incomplete and continues to evolve. For example, not all instances of CSF HHV-6 DNA detection are associated with significant CNS morbidity, as we have previously reported in our HCT patient population^[@R14]^. However, viral detection in the CSF and blood compartments may underestimate the true incidence of tissue-level reactivation and pathogenicity. HHV-6 is a neurotropic virus with latency in astrocytes and glial cells^[@R15],[@R16]^, and brain tissue from patients with HHV-6 encephalitis has been shown to have higher levels and prolonged detection of HHV-6 DNA compared to blood or CSF samples^[@R17],[@R18]^. Indeed, the detection of herpesvirus DNA in liquid compartments (e.g. blood, CSF, bronchoalveolar lavage fluid) may not be a sensitive or specific biomarker for end-organ disease. Mechanistically, one can hypothesize that direct effects of tissue-level reactivation and/or indirect effects of systemic reactivation, such as the induction of pro-inflammatory cytokines^[@R20],[@R21]^, may contribute to delirium in affected patients. Interestingly, some of these same cytokines have been associated with delirium in critically ill patients^[@R22]^.

The incidence of HHV-6 encephalitis after CBT in this cohort (2.3%) is similar to that recently reported at Memorial Sloan-Kettering Cancer Center^[@R4]^ but lower than incidence rates of 8--10% at other centers^[@R1],[@R2],[@R13]^. This finding may be due to differences in strategies for antiviral prophylaxis (such as we report here) or preemptive therapy (such as reported at Sloan-Kettering). Variability in conditioning regimens may also play a role. Neither our center nor Sloan-Kettering use antithymocyte globulin for CBT, which has been variably associated with HHV-6 reactivation^[@R2],[@R25]^.

Intensified antiviral prophylaxis with high-dose valacyclovir has been shown to similarly diminish HHV-6 reactivation in one other study of HCT recipients receiving 2 grams of valacyclovir four times a day^[@R23]^. Whether or not this intervention may reduce HHV-6-associated complications is unknown, and our study was not powered to address this question. Ogata and colleagues demonstrated that low-dose foscarnet prophylaxis did not significantly reduce high-level HHV-6 DNA detection or HHV-6 encephalitis in a population of unrelated and cord blood HCT recipients^[@R24]^; however, the results were suggestive and indicate that further study is required.

The findings in this and our previous study of HHV-6-associated delirium in a diverse cohort of allogeneic HCT recipients^[@R5]^ are clinically meaningful in light of studies linking delirium to morbidity after HCT^[@R10]^. Whether routine screening for HHV-6 reactivation after CBT is warranted remains to be determined. The development of new broad-spectrum antiviral agents with limited side effects, such as brincidofovir (CMX001)^[@R26]^, provide unique opportunities for clinical trials exploring whether prophylactic or preemptive approaches to mitigating HHV-6 reactivation can improve HCT outcomes.

This study's strengths include a prospective design, frequent quantitative HHV-6 assessments, and standardized neuropsychiatric testing blinded to HHV-6 reactivation. The relatively small sample size limited our analyses and conclusions, and this may explain the lack of a statistically significant association with delirium after adjusting for comorbidity and conditioning ([Figure 1](#F1){ref-type="fig"}). Despite this, our findings support a quantitative association between HHV-6 viral load and the endpoints of interest. The lack of an international standard for HHV-6 DNA measurement precludes extrapolation of quantitative levels to other studies, as inter-laboratory correlation is known to be poor^[@R27]^. Lack of CSF HHV-6 testing in all patients with delirium was another limitation.

In conclusion, HHV-6 reactivation after CBT is quantitatively associated with delirium, and antiviral prophylaxis with high-dose valacyclovir may mitigate HHV-6 reactivation. Larger interventional studies are needed to assess the utility of low-toxicity HHV-6 prevention strategies for reducing delirium and other adverse outcomes in high-risk HCT recipients.
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![Multivariable models evaluating HHV-6 as a predictor of delirium\
Bivariable logistic regression models evaluating detection of HHV-6 DNA \>median maximum as a risk factor for delirium, adjusted for the other variable shown.](nihms688139f1){#F1}

![Cumulative incidence curves of HHV-6 reactivation stratified by antiviral prophylaxis strategy\
Cumulative incidence curves for detection of HHV-6 DNA at any or \>median maximum level, stratified by antiviral prophylaxis strategy.](nihms688139f2){#F2}

###### 

Demographic, clinical, and virologic characteristics of the cohort, overall and stratified by ever having HHV-6 reactivation at any level, HHV-6 \>median maximum (785 copies/mL), or delirium after CBT

  Characteristic[†](#TFN3){ref-type="table-fn"}   Overall, no. (%)(N = 44)   HHV-6 reactivation, no. (%) (n = 44)   Delirium episode, no. (%) (n=35)[\*](#TFN2){ref-type="table-fn"}                                   
  ----------------------------------------------- -------------------------- -------------------------------------- ------------------------------------------------------------------ ----------- ------------------- ------------------
  Age, y, median (IQR)                            35 (12--53)                30 (12--45)                            33 (13--45)                                                        42 (2--6)   38 (30--66)         42 (23--59)
  Female sex                                      22 (50)                    15 (52)                                13 (59)                                                            7 (47)      4 (44)              15 (58)
  Caucasian                                       28 (64)                    19 (66)                                14 (64)                                                            9 (60)      6 (67)              17 (65)
  Recipient CMV seropositive                      32 (73)                    24 (83)                                17 (77)                                                            8 (53)      8 (89)              18 (69)
  High medical comorbidity                        19 (43)                    10 (34)                                8 (36)                                                             9 (60)      7 (78)              11 (42)
  TBI dose ≥1200 cGY                              22 (50)                    15 (52)                                11 (50)                                                            7 (47)      5 (56)              12 (46)
  More advanced underlying disease                27 (61)                    16 (55)                                12 (55)                                                            11 (73)     5 (56)              16 (62)
  Myeloablative conditioning regimen              26 (59)                    19 (66)                                14 (64)                                                            7 (47)      6 (67)              12 (46)
  Double unit CBT                                 33 (75)                    23 (79)                                19 (86)                                                            10 (67)     9 (100)             23 (88)
  HLA 4/6 Mismatch                                23 (52)                    16 (55)                                11 (50)                                                            7 (47)      6 (67)              15 (58)
  Intensive antiviral prophylaxis                 17 (39)                    12 (41)                                6 (27)                                                             5 (33)      5 (56)              10 (38)
  Acute GVHD, grade 3--4                          12 (27)                    7 (24)                                 7 (32)                                                             5 (33)      3 (33)              5 (19)
  HHV-6 reactivation, any                         \--                        \--                                    \--                                                                \--         6 (67)              18 (69)
  HHV-6 reactivation \>median max                 \--                        \--                                    \--                                                                \--         5 (56)              13 (50)
  HHV-6 DNA median max copies/mL (IQR)            785 (0--6,154)             \--                                    \--                                                                \--         3,275 (0--17,224)   1,074 (0--5,900)
  HHV-6 day of first detection, (IQR)             \--                        20 (17--28)                            24 (19--27)                                                        \--         \--                 \--

IQR indicates interquartile range; CMV, cytomegalovirus; TBI, total body irradiation; CBT, cord blood transplantation; HLA, human leukocyte antigen; GVHD, graft-versus-host-disease.

Nine patients were too young, too sick, or otherwise unable to participate in delirium assessments.

Characteristics were defined as previously described (Zerr *et al*, 2011).

This category includes patients in the HHV-6 \>median maximum category.

###### 

Cox proportional hazards model for risk factors for HHV-6 reactivation \>median maximum (785 copies/mL)

  Variable                            HR (95% CI)          *P* value   aHR (95% CI)         *P* value
  ----------------------------------- -------------------- ----------- -------------------- -----------
  Double CBT (vs. single)             3.45 (1.01--11.76)   0.05        5.03 (1.43--17.72)   0.01
  Acute GVHD grade 3--4               2.41 (0.94--6.19)    0.07        2.06 (0.75--5.69)    0.16
  Intensified antiviral prophylaxis   0.46 (0.18--1.17)    0.10        0.39 (0.14--1.08)    0.07

HHV-6 indicates human herpesvirus 6; HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; CBT, cord blood hematopoietic cell transplantation; GVHD, graft-versus-host disease.

###### Key Points

-   HHV-6 reactivation after cord blood transplantation is associated with delirium.

-   High-dose valacyclovir may mitigate HHV-6 reactivation.

-   Larger studies are needed to assess the impact of HHV-6 prevention on outcomes.
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